Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
343 hedge funds and large institutions have $10.8B invested in Avidity Biosciences in 2025 Q4 according to their latest regulatory filings, with 157 funds opening new positions, 70 increasing their positions, 86 reducing their positions, and 81 closing their positions.
267% more funds holding in top 10
Funds holding in top 10: 9 → 33 (+24)
94% more first-time investments, than exits
New positions opened: 157 | Existing positions closed: 81
54% more capital invested
Capital invested by funds: $7.01B → $10.8B (+$3.78B)
26% more funds holding
Funds holding: 272 → 343 (+71)
10.96% less ownership
Funds ownership: 110.32% → 99.36% (-11%)
19% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 86
76% less call options, than puts
Call options by funds: $64.3M | Put options by funds: $264M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$390M |
| 2 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$389M |
| 3 |
HI
HBK Investments
Dallas,
Texas
|
+$282M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$240M |
| 5 |
BlackRock
New York
|
+$236M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.38B |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$623M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$603M |
| 4 |
RI
RTW Investments
New York
|
-$496M |
| 5 |
Janus Henderson Group
London,
|
-$490M |
RNAM Hedge Fund Activity: Q4 2025 in Review
343 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q4 2025, worth a combined $10.8B — up 54% from $7.01B a quarter earlier.
Buyers outnumbered sellers: 157 funds opened new RNAM positions and 81 closed out — a net gain of 76 holders — while 70 added to existing stakes and 86 trimmed.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $390M. The largest seller was Fidelity Investments, cutting an estimated $1.38B.
- 343 institutional investors held Avidity Biosciences (RNAM) as of Q4 2025, up from 272 in Q3 2025.
- Funds reported $10.8B of Avidity Biosciences stock for Q4 2025, up 54% quarter-over-quarter.
- 157 funds opened new Avidity Biosciences positions in Q4 2025 and 81 closed out, a net change of +76 holders.
- The largest Avidity Biosciences buyer in Q4 2025 was Balyasny Asset Management, an estimated $390M added.
- The largest Avidity Biosciences seller in Q4 2025 was Fidelity Investments, an estimated $1.38B sold.
Based on aggregated 13F filings for Q4 2025.